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Abstract
Background Intravenous hypertonic saline is utilized commonly in critical care for treatment of acute or refractory elevations of
intracranial pressure (ICP) in traumatic brain injury (TBI) patients. Though there is a clear understanding of the general phys-
iological effects of a hypertonic saline solution over long periods of time, smaller epoch effects of hypertonic saline (HTS) have
not been thoroughly analyzed. The aim of this study was to perform a direct evaluation of the high-frequency response of HTS on
the cerebrovascular physiological responses in TBI.
Methods We retrospectively reviewed our prospectively maintained adult TBI database for those with archived high-frequency
cerebral physiology and available HTS treatment information. We evaluated different epochs of physiology around HTS bolus
dosing, comparing pre- with post-HTS. We assessed for changes in slow fluctuations in ICP, pulse amplitude of ICP (AMP),
cerebral perfusion pressure (CPP), mean arterial pressure (MAP), cerebrovascular reactivity (as measured through pressure
reactivity index (PRx)), and cerebral compensatory reserve (correlation (R) between AMP (A) and ICP (P)). Comparisons of
meanmeasures and percentage time above clinically relevant thresholds for the physiological parameters were compared pre- and
post-HTS using descriptive statistics and Mann-Whitney U testing. We assessed for subgroups of physiological responses using
latent profile analysis (LPA).
Results Fifteen patients underwent 69 distinct bolus infusions of hypertonic saline. Apart from the well-documented decrease in
ICP, there was also a reduction in AMP. The analysis of cerebrovascular reactivity response to HTS solution had two main
effects. For patients with grossly impaired cerebrovascular reactivity pre-HTS (PRx > + 0.30), HTS bolus led to improved
reactivity. However, for those with intact cerebrovascular reactivity pre-HTS (PRx < 0), HTS bolus demonstrated a trend towards
more impaired reactivity. This indicates that HTS has different impacts, dependent on pre-bolus cerebrovascular status. There
was no significant change inmetrics of cerebral compensatory reserve. LPA failed to demonstrate any subgroups of physiological
responses to HTS administration.
Conclusions The direct decrease in ICP and AMP confirms that a bolus dose of a HTS solution is an effective therapeutic agent
for intracranial hypertension. However, in patients with intact autoregulation, hypertonic saline may impair cerebral hemody-
namics. These findings regarding cerebrovascular reactivity remain preliminary and require further investigation.
This article is part of the Topical Collection on Brain trauma
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Introduction
Hypertonic saline (HTS) solutions are used in the setting of
moderate/severe traumatic brain injury (TBI) to treat instances
of acute or refractory elevations in intracranial pressure (ICP)
[9, 38]. There is substantial evidence to indicate that long
periods of high ICP result in poor neurological outcomes in
TBI [1, 14, 20, 23, 24], and that aggressive ICP and cerebral
perfusion pressure (CPP)-directed management should be the
mainstay of care for moderate/severe TBI. Though the impact
of HTS on ICP response is well known, its impact on other
aspects of cerebral physiology remains uncertain. Much of
this uncertainty stems from the difficulty in obtaining high-
frequency digital physiology, in concert with treatment infor-
mation and timing. Most prior work has focused on mean
hourly or peak hourly point measures of ICP and CPP,
documenting the response to HTS administration [7]. The
response of cerebrovascular reactivity and cerebral compen-
satory reserve measures to HTS administration remains under-
investigated, with preliminary work demonstrating a decrease
in ICP and a tendency to decrease pressure reactivity index
(PRx), as well as a decrease in cerebral blood flow and cere-
brovascular resistance [17].
For cerebrovascular reactivity, data supporting the strong
association between impaired cerebrovascular reactivity and
poor patient outcome in TBI is emerging [5, 15, 19, 39, 46,
50], as well as computed tomography (CT)-based peri-
contusional edema progression [34, 35]. Furthermore, recent
literature also supports limited to no impact of Brain Trauma
Foundation (BTF) guideline-based therapies on cerebrovascu-
lar reactivity, including hyperosmolar/hypertonic agents [19,
22, 43, 47]. The main limitation of previous work in this area
is the poor temporal resolution of the treatment data, relying
on daily measures of treatment intensity levels. Thus, our true
understanding of the impact of HTS on continuously assessed
cerebrovascular reactivity, whether positive or negative, re-
mains unknown.
Similarly, continuously assessed cerebral compensatory re-
serve, using the RAP (correlation (R) between pulse ampli-
tude of ICP (A) and ICP (P)), has emerged as a potential
surrogate metric for compliance [11, 31, 49, 50]. Recent data
suggests association of high area under the RAP vs. time
curve, with admission CT characteristics of diffuse intracrani-
al injury, as well as poor global outcome at 6 months post-TBI
[50]. However, there is limited data assessing its response to
HTS, an agent designed to reduced ICP, and subsequently
improve compliance. Knowledge of the responsiveness of this
type of advanced cerebral physiological monitoring to HTS
dosing may improve end-user uptake and provide some addi-
tional confidence in this metric’s ability to measure important
aspects of intracranial physiology during injured states.
As such, the goal of this study was to assess the HTS
response of slow fluctuations in cerebral physiology, cerebro-
vascular reactivity, and cerebral compensatory reserve, using
archived high-frequency physiology data and treatment infor-
mation stored in the Winnipeg Acute TBI Database.
Materials and methods
Study design
We retrospectively reviewed our prospectively maintained
TBI database from the Winnipeg Acute TBI Laboratories at
the University of Manitoba. We selected those patients with
archived high-frequency digital physiology (ICP and ABP)
and treatment data pertaining to HTS administration. All pa-
tients included in this database are age 17 or older, who have
suffered moderate to severe TBI, requiring admission to the
surgical intensive care unit (SICU) for invasive ICP monitor-
ing. Patients have been sequentially entered into this database
since January 2019, with no gaps or missed patients. Patients
received treatment according to the Brain Trauma Foundation
(BTF) guidelines [14] A total of 15 patients were identified
with HTS data and high-frequency physiological recordings
facilitating the assessment of cerebrovascular reactivity and
compensatory reserve. There were 69 distinct episodes of bo-
lus dose HTS administered, with all receiving the standard
institutional bolus dose of 140 ml of 7.33% HTS solution
for intermittent episodes of refractory ICP. All aspects of data
collection for this database have been approved by the
University of Manitoba research ethics board (H2017:181
and H2017:188), with approval for retrospective access for
this project (H2020:118).
As mentioned, our patients received therapy according to
the BTF guidelines. All patients with mass-occupying lesions
are taken to the operating room on admission for evacuation ±
primary decompression, depending on the individual situa-
tion. Our local tiered approach to ICP/CPP management is
as follows, with a goal ICP of < 22 mmHg and CPP between
60 and 70 mmHg. First, elevation of the head of bed is 30° or
higher (depending on tolerance) with assurance of no con-
straints on the neck to jugular venous return. Next, sedation
is titrated to ensure comfort on the ventilator, followed by
escalation in dosing titrated to ICP. We employ a combination
of propofol, fentanyl, and midazolam as our baseline
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infusions. Spikes in ICP above 22 mmHg for 10 min, are
tempered using either mannitol or HTS intermittent dosing.
Our local institutional preference is for HTS. Failure of the
above therapies is followed by ongoing sedative/hypertonic
measures, with the addition of hypothermia therapy (via ex-
ternal cooling) or consideration for decompressive proce-
dures. We do not employ barbiturate therapy in our patients.
We rarely utilize hyperventilation therapy outside of tempo-
rizing measures to facilitate more definitive management (i.e.,
surgical intervention). We do not routinely employ cerebro-
spinal fluid diversion through external drainage to control
ICP. We do not utilize cerebrovascular reactivity or compen-
satory reserve monitoring to direct therapies.
Patient data collection
As part of the ongoing prospective TBI database, all patient
demographic, injury, and treatment information is recorded.
For the purpose of this study, we extracted standard patient
demographics (including age, sex, admission Glasgow Coma
Score (GCS) total and motor, pupillary response, presence of
pre-hospital hypoxia/hypotension, and admission computed
tomography (CT) characteristics—including Marshall CT
scores). All HTS dosing is recorded with a time stamp,
allowing it to be linked to high-frequency recorded
physiology.
All patients had ICP and arterial blood pressure (ABP) data
prospectively recorded using intensive care monitoring plus
(ICM+) software (Cambridge Enterprise Ltd, Cambridge,
UK, http://icmplus.neurosurg.cam.ac.uk), with all signals
recorded using the same software and digitized via an A/D
converter (DT9804 or DT9826; Data Translation, Marlboro,
MA), where appropriate; sampled at frequency of 100 Hz or
higher. ICP was monitored using an intra-parenchymal strain
gauge probe (Codman ICP Microsensor; Codman & Shurtleff
Inc., Raynham, MA); ABP was obtained through arterial lines
connected to a pressure transducer.
Signal processing
CPP was calculated as mean arterial pressure (MAP)-ICP.
Pulse amplitude of ICP (AMP) was derived from the funda-
mental amplitude of the ICP waveform in the frequency do-
main, using Fourier analysis. A non-overlapping 10-s moving
average filter was applied to the raw data to decimate the
signals to 0.1 Hz, focusing on the frequency ranges associated
with cerebral vasogenic activity [21, 27]. ICP, AMP, MAP,
and CPP were subsequently output into 10-s by 10-s comma-
separated value files for further analysis of the impact of HTS
on cerebral physiology slow fluctuations.
Cerebrovascular reactivity was assessed through the deri-
vation of the PRx. PRx was determined using standard means,
by calculating the Pearson correlation coefficient between 30
consecutive 10-s measures of ICP and MAP, updated every
minute [15]. Similarly, cerebral compensatory reserve was
determined using the RAP index (correlation (R) between
AMP (A) and ICP (P)), calculated following a similar fashion
to PRx, but using AMP and ICP [11]. Data for PRx and RAP
was output into minute-by-minute resolution comma-
separated value files, for the analysis of the impact of HTS
on both cerebrovascular reactivity and cerebral compensatory
reserve.
Statistical analysis
All statistical analysis was performed using R statistical com-
puting software (R Foundation for Statistical Computing
(2020), Vienna, Austria, http://www.R-project.org/).
Descriptive summary statistics for the patient population are
provided in Table 1. Alpha for statistical significance was set
at 0.05, with no correction for multiple comparisons, given
this was an exploratory analysis. Error-bar plots were used
to aid in the description of the data.
Initially, data surrounding each bolus injection was found
and abstracted for 2 h before and after injecting, with incom-
plete data sets (i.e., missing ICP and ABP data) being re-
moved. Then the data was aligned using the max peak ICP
around the recorded injection time. If the ICP waveform had
no distinct drop then this was deemed a non-responsive event,
with the data stored separately for sub-group analysis. The
cerebral physiology surrounding each HTS administration
was manually inspected for ICP response. The criteria for a
positive HTS response were (A) ICP had to drop by at least
2 mmHg during the initial 10 min post-HTS infusion and (B)
ICP had to continue to drop by at least 5 mmHg from baseline
during the following 30 min. Using these criteria, in total,
there were 55 distinct episodes of responsive ICP to HTS
and 14 distinct episodes that had non-responsive ICP to
HTS. Examples of ICP response are demonstrated in Fig. 1.
For each HTS injection, two distinct comparisons were
conducted for the recorded physiology pre-/post-HTS. First,
the time over threshold before and after bolus infusion was
compared, using the following thresholds: (A) ICP above
22 mmHg [14], (B) AMP above 2 mmHg (though 1–
10 mmHg was tested) [29], (C) CPP below 60 mmHg [18],
(D) PRx above + 0.3 [4, 48], and (E) RAP above + 0.4 [50].
These thresholds were chosen as they have been quoted in
TBI literature to be associated with worse global outcome.
The window lengths of data to compare varied from 5 to
60 min with a delay varied from 5–60 min to evaluate re-
sponse; the final window time and delay used for all the final
evaluations in this analysis can be seen in Fig. 1 (10-min delay
between two 20-min windows). For each window, the time
over the indicated threshold was found for each bolus injec-
tion. Finally, a Mann-Whitney U test was performed between
the two windows of data. The other variations in data
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windows, and gaps, failed to lead to any significant differ-
ences in the relationships described in the “Results” section.
As such, we focused on the above defined data windows (i.e.,
20 min pre-HTS, 10 min gap allowing for HTS infusion, and
20 min post-HTS) when presenting the results. Second, we
compared the grand mean physiological value across the time
windows using Mann-Whitney U test.
Furthermore, we wished to see if there was a difference in
physiological response to HTS for those patients with de-
ranged cerebrovascular reactivity pre-HTS (i.e., mean PRx
for 30 min before HTS was above + 0.3) [10], clearly intact
cerebrovascular reactivity pre-HTS (i.e., mean PRx for 30min
before HTS was below 0) [10]. We subsequently performed
the previously stated analyses (time over threshold and grand
mean value over window with a Mann-Whitney U test for
each) with the same 20-min windows and 10-min delay.
Finally, for the MAP, ICP, CPP, and AMP slow-wave data
(i.e., 10-s data), latent profile analysis (LPA) [36] was per-
formed to identify any key features/classes of responses to
HTS. In order to perform an accurate analysis on the data,
values that contained null values were interpolated using lin-
ear regression of its nearest 5 neighbors to substitute for the
missing data value [26]. The now fully filled data sets were
then scaled so that each individual bolus infusion data set had
a maximum variance of 1. Lastly, the filled and scaled data
was then averaged over 5 min to reduce the dimensionality for
LPA, then an LPA was performed to identify any sub-group
of HTS responses for MAP, ICP, AMP, and CPP that the
waveforms may contain. LPA failed to identify sub-groups
Fig. 1 Examples of responsive vs. non-responsive ICP to HTS. The
pressure waveforms of responsive vs. non-responsive ICP to HTS. The
shaded areas indicate the two 20-min windows with a 10-min delay used
to evaluate the change due to HTS. AMP, amplitude pulse of ICP; CPP,
cerebral perfusion pressure; HTS, hypertonic saline; ICP, intracranial
pressure; MAP, mean arterial blood pressure; Mins/mins, minutes;
mmHg, millimeters of mercury; PRx, pressure reactivity index
Table 1 Patient demographics and clinical characteristics with 15
different patients and 69 distinct bolus infusions of HTS
Characteristics N (%) or median
(interquartile range)
n (patients) 15
Age 35 (23–54)
Sex (male) 11 (73.3%)
Best GCS 7 (6–8)
Best GCS-motor 5 (4–5)
Pupillary light reflex
Bilateral reactive 9 (60%)
Unilateral unreactive 4 (26.6%)
Bilateral unreactive 2 (13.3%)
Pre-hospital hypoxia 10 (66.6%)
Pre-hospital hypotension 2 (13.3%)
CT-epidural hematoma 2 (13.3%)
Mean ISS 25 (25–27)
AIS-head/brain 5 (4.5–5)
Marshall classification category of 1st head-CT
III 4 (26.6%)
IV 6 (40%)
V 5 (33.3%)
Median GOSE outcome 1 month 4 (1–5)
Treatment was a 140-ml 7.5% hypertonic saline solution
AIS, abbreviated injury scale; CT, computed tomography; HTS, hyper-
tonic saline; ISS, injury severity score;GCS, Glasgow coma score;GOSE,
Glasgow Outcome Scale-Extended
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of responses to HTS for any of the physiology assessed, and
thus details of this negative analysis are not presented. Finally,
we compared the influence of HTS on ICP and its association
with other measured physiology or cerebral reactivity. The
delta ICP for each bolus infusion of HTS was determined as
the difference between the ICP mean value of two 30-min
windows, one immediately before HTS infusion and one
30 min after HTS infusion. The mean/time over threshold
was found over a variety of time windows immediately before
HTS infusion (10 to 120 min). Using all HTS bolus infusions,
mean/time over threshold vs. delta ICP were used to find a
Pearson correlation and p value.
Results
Patient characteristics
Table 1 provides a table with the core patient characteristics.
In total, there were 15 patients with 69 separate episodes of
HTS administration analyzed. The median age was 35 (IQR,
23–54), with 11 being male. The median admission GCS mo-
tor sub-score was 5 (IQR, 4–5), with 10 and 2 having pre-
hospital episodes of hypoxia and hypotension, respectively.
Finally, Marshall CT grades on admission were 4 patients
with class III, 6 with IV, and 5 with V.
Physiological response
HTS had no significant effect on slow fluctuations in MAP.
There was, however, a significant response in slow fluctua-
tions in ICP, CPP, and AMP. Table 2 demonstrates the re-
sponse that HTS induced on these waveforms. In Table 2, the
delay was 10 min and the time window 20 min, though as
mentioned above, altering the time windows/delay failed to
change the described relationships. ICP and AMP consistently
demonstrated a decrease in magnitude, while CPP had an
increase. As can be interfered from Fig. 1, an increase in the
delay improved the significance up to about 40min post-HTS,
likewise an increase in the time window also increases the
significance in ICP, AMP, and CPP responses. The 10-min
delay, with a 20-min time window, demonstrated the most
immediate significant response to cerebral physiology post-
HTS infusion.
Despite the significant decrease in ICP and AMP demon-
strated in 55 treatment episodes, in some patients, the bolus
dose of HTS resulted in a non-significant response of ICP, as
Fig. 1 illustrates. This lack of response in both ICP and AMP
was similar in all infusion examples with a non-responsive
ICP waveform (n = 14). In Supplementary Appendix A, more
examples of responsive and non-responsive waveforms are
shown.
Cerebrovascular reactivity status pre-HTS
To evaluate HTS on cerebrovascular reactivity, we separated
the responsive ICP data into three different categories, im-
paired (mean PRx pre-HTS above + 0.3; n = 15), intact (mean
PRx pre-HTS below 0; n = 17) or in the “grey” zone (mean
PRx pre-HTS between 0 and + 0.3; n = 23). Table 2 demon-
strates impaired and intact cerebrovascular reactivity re-
sponses to HTS. For a more intuitive description of the effects
of PRx and HTS on cerebral response, there are examples in
the Supplementary Appendix B using the error bar plots of
each physiological measure and its effect to HTS, both for
impaired and intact cerebrovascular reactivity across the entire
population. In these error bar plots, ICP, AMP, MAP, and
CPP all demonstrated the same physiological response as
discussed previously. As can be seen in Table 2, when PRx
is initially high, HTS caused a decrease in PRx mean and time
over threshold. RAP failed to demonstrate a significant differ-
ence, regardless of the data window utilized for comparison.
However, when cerebrovascular reactivity was intact pre-
HTS, HTS bolus had the tendency to increase PRx. Though
again, the change in window and delay caused a change in
significance. As with the intact cerebrovascular reactivity
group, the response in RAP was not significant on any time
window of delay tested. Similar analysis for those HTS ad-
ministration episodes where pre-HTS PRx was in the “grey”
zone of 0 to + 0.30 can be found in Supplementary Appendix
C.
Discussion
Through this analysis of the impact of HTS on high-frequency
cerebrovascular physiology, some direct responses of note
were revealed. First, there is a significant and reliable decrease
in AMP with ICP with HTS bolus dosing, corroborating pre-
vious literature on the topic [11, 17, 49]. The two waveforms
are heavily correlated as demonstrated by the persistently pos-
itive RAP (i.e., correlation between ICP and AMP) in all bolus
infusions in which ICP responded to HTS (n = 55). This con-
clusion supports the idea that AMP may be effective at iden-
tifying true ICP (also termed compensatory reserve weighted
ICP), though much further work in this area is required [25,
30, 37]. Also in line with the ICP reduction is the significant
improvement in CPP seen post-HTS dosing. Of note, LPA
analysis failed to uncover any sub-groups of responders with
different temporal profiles in cerebral physiological response
to HTS administration, including the response of ICP, AMP,
MAP, and CPP.
Second, a small number of instances (n = 14) existed where
there was no response in ICP to HTS administration. Based on
inspection of the cerebral physiology pre-HTS in these cases,
a clear common physiological pattern in these instances did
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not exist. However, there are some non-responsive episodes
where the PRx was high (impaired reactivity) [3, 15, 39, 50],
potentially reflecting a system where the homeostatic mecha-
nisms are deranged beyond the point of salvage or response to
therapeutics. Given the small number of these types of events
seen in our data set, much larger multi-center cohorts of data
with treatment information are required to explore reasons for
responsive and non-responsive periods.
Third, cerebrovascular reactivity appears to improve with
HTS administration, in the short term (up to 60 min post-
HTS). These HTS results have been described previously in
one study [17], with the inter-dependence of ICP and cerebro-
vascular reactivity alluded to in other retrospective series [4,
10, 40, 47]. However, this improvement in cerebrovascular
reactivity tended to only occur when there was gross derange-
ment in reactivity pre-HTS (i.e., PRx > + 0.30 for 30 min pre-
HTS). Those treatment instances where cerebrovascular reac-
tivity remained intact pre-HTS displayed a trend towards more
positive PRx values post-HTS. This has not been previously
described and carries importance moving forward for ongoing
studies into cerebrovascular reactivitymonitoring and individ-
ualized CPP/ICP thresholds based on PRx. Furthermore, it
carries implications for prophylactic dosing of HTS in
moderate/severe TBI. It is becoming more apparent that the
time spent with abnormal cerebrovascular reactivity is associ-
ated with poorer 6-month outcome in moderate/severe TBI
[20, 24, 45, 48]. As such, if particular treatments lead to worse
cerebrovascular reactivity, this may impact patient outcomes.
Evaluating the cause for the rise in PRx post-HTS has left us
with more questions than answers. Given that HTS reduced
ICP, one natural thought as to the cause for the rise in PRx
would be a subsequent rise in MAP/CPP towards the upper
limit of regulation (ULR) [18]. However, as seen in
Supplementary Appendix B, at a population level, this is not
the case. In the cohort of “intact” reactivity prior to HTS, we
can see that HTS administration failed to lead to a significant
increase in either MAP or CPP, yet did lead to an increase in
PRx. With that said, evaluating each response at an individual
level, there were some cases where HTS administration did
lead to MAP/CPP increases that in theory could have
approached the ULR (see Supplementary Appendix A—ex-
ample of HTS response). Worsening of cerebrovascular reac-
tivity after HTS administration has been described in aneurys-
mal subarachnoid hemorrhage patients, using transcranial
Table 2 Physiological responses
to HTS—all events, impaired and
intact cerebrovascular reactivity
Pre-HTS infusion Post-HTS infusion Mann-Whitney
U
(p value)
Median (interquartile range)
All HTS administration events
ICP time above 22 mmHg (min) 16.33 (4.25 to 20.17) 4.67 (0.75 to 8.67) 0.0011*
ICP mean for 20 min window
(mmHg)
23.23 (20.56 to 25.83) 18.52 (16.46 to
21.44)
< 0.0001*
CPP time below 60 mmHg (min) 0 (0 to 9.5) 0 (0 to 8.17) 0.91
CPP mean for 20 min window
(mmHg)
67.65 (57.06 to 73.72) 72.95 (66.17 to
81.95)
0.02
AMP time above 2 mmHg (min) 20 (10.67 to 20) 12.92 (6.08 to 20) 0.22
AMP mean for 20 min window
(mmHg)
2.84 (2.27 to 4.35) 2.27 (1.81 to 3.69) 0.09
PRx impaired (i.e., > + 0.30) prior to HTS
PRx time above + 0.30 (min) 20 (19 to 20) 17 (13.5 to 18) < 0.0001*
PRx mean for 20 min window (a.u.) 0.83 (0.73 to 0.92) 0.53 (0.39 to 0.63) < 0.0001*
RAP mean for 20 min window (a.u.) 0.73 (0.65 to 0.93) 0.84 (0.62 to 0.89) 0.72
PRx intact (i.e., < 0) prior to HTS
PRx time above + 0.30 (min) 0.5 (0.0 to 3.0) 3.5 (2.0 to 6.0) 0.01*
PRx mean for 20 min window (a.u.) − 0.08 (− 0.21 to −
0.04)
− 0.04 (− 0.13 to
0.12)
0.19
RAP mean for 20 min window (a.u.) 0.83 (0.72 to 0.93) 0.88 (0.83 to 0.96) 0.22
For ICP, CPP, and AMP, the time is above their respective threshold and the mean value for the two 20-min
windows with a 10-min delay. The time above/below threshold/mean value of PRx and the mean value RAP over
the 20-min windows with a 10-min delay for PRx above + 0.3, and with a PRx below 0.0, before HTS infusion;
median (interquartile range). A Mann-Whitney U test has been performed between each time segment
AMP, amplitude pulse of ICP; CPP, cerebral perfusion pressure; HTS, hypertonic saline; ICP, intracranial pres-
sure; MAP, mean arterial pressure; min, minutes; mmHg, millimeters of mercury; PRx, pressure reactivity index
(correlation between ICP and MAP); RAP, compensatory reserve index (correlation between AMP and CPP)
*p values are those reaching statistical significance (i.e., p < 0.05)
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Doppler (TCD) mean flow index (Mx; correlation between
mean flow velocity from the middle cerebral artery and
CPP) [41]. This prior study in subarachnoid hemorrhage dem-
onstrated significant ICP reductions with increased MAP,
CPP, and CBF (using Xenon CT). However, there was a sig-
nificant hemispheric discrepancy in Mx pre-HTS, with the
ipsilateral hemisphere (ipsilateral to hemorrhage/aneurysm)
displaying “impaired” reactivity pre-HTS (+ 0.20 ± 0.92),
and the contralateral hemisphere displaying relatively “intact”
reactivity pre-HTS (+ 0.01 ± 0.95). With HTS administration,
the ipsilateral hemisphere did not show any change in Mx;
however, the contralateral hemisphere had worsening cerebro-
vascular reactivity with HTS administration (increase of +
0.22 ± 0.28, p < 0.01). These previous findings, in conjunction
with our results in this TBI cohort, suggest that HTS may
induce impaired cerebrovascular reactivity if reactivity is in-
tact prior to HTS administration. It must be emphasized that
our findings are based on a small number of patients and
treatments but raise the question of a disparity in cerebrovas-
cular reactivity response to HTS bolus dosing. Although not
directly confirmed, the only other previous study that ana-
lyzed the effects of HTS on cerebrovascular reactivity in
TBI may also have demonstrated this phenomenon though
all of these episodes were amalgamated into one group [17].
Finally, the episodes where PRxwas in a grey zone (i.e., 0 to +
0.30) prior to HTSwere analyzed in Supplementary Appendix
C. These episodes of PRx were not the main focus of the
study, as we wanted to do a sub-group analysis based on
clearly intact vs. clearly impaired cerebrovascular reactivity.
Our analysis of this grey zone sub-group demonstrated that
there was no significant impact of HTS on recorded cerebro-
vascular reactivity or compensatory reserve. This grey zone
for PRx remains unclear in the literature, and may represent a
transitional phase for cerebrovascular reactivity, as PRx is
unlikely a binary function and likely represents a spectrum
of vascular function. Further investigation into this disparity
of response to HTS is required in order to fully understand the
impact of HTS on cerebrovascular reactivity in TBI.
Fourth, the impact of HTS on continuously assessed cere-
bral compensatory reserve (i.e., RAP) was underwhelming in
our cohort. Despite the improvement in AMP and ICP with
HTS administration, RAP itself (i.e., a surrogate for phase
shift between AMP and ICP), failed to demonstrate a signifi-
cant difference comparing values pre- with post-HTS. There
appeared to be a trend towards a decrease in RAP when PRx
was impaired pre-HTS, however this was not significant.
These findings are in slight contradiction with those found
with barbiturate therapy in TBI [28]. The prior work on
RAP and its response to barbiturate therapy in TBI did dem-
onstrate a reduction in RAP, AMP, and ICP slope with thio-
pental coma. Thus, RAP does appear to demonstrate a tempo-
ral responsiveness to BTF-directed therapeutic interventions.
It must be acknowledged that HTS and barbiturate therapies
have different mechanisms of action, which may account for
the different responses seen in our paper compared with the
barbiturate literature. HTS primarily functions based on im-
proved rheology and osmotic properties, while barbiturates
function based on metabolic suppression. Similarly, the tem-
poral response pattern of RAP is difficult to assess, as changes
in brain edema may take extended time periods to occur, and
may depend on individual genetics [16, 44]. We are currently
left with assessing mean RAP or time above threshold, though
integrated area under RAP vs. time curves have been utilized
[50]. Given the negative parabolic nature of the relationship
between RAP and ICP, low or negative value RAP can mean
both preserved and severely impaired compensatory reserve,
depending on the situation [11]. Thus, the interpretation of
RAP is complex. We were interested in performing a sub-
group analysis of those with grossly impaired pre-HTS mean
RAP (i.e., > + 0.4) vs. those with pre-HTS RAP < + 0.4,
however, all of our instances of HTS administration had a
mean RAP value above + 0.4. Thus, such an analysis was
not possible. Other RAP thresholds were not investigated, as
the selection of other higher RAP values would have been
arbitrary. Such investigation into RAP thresholding requires
dedicated larger multi-center data sets and is beyond the scope
of this paper. Unfortunately, given the relatively new nature of
RAP in TBI monitoring, we are still in stages of infancy re-
garding its application and analysis. Thus, the role for contin-
uous RAPmonitoring remains unclear at this time, with much
further investigation required in TBI multi-modal monitoring.
As such, the negative results regarding RAP found in this
study should be interpreted with caution.
Finally, we were unable to find any pre-HTS physiolog-
ical variables which were predictive of the ICP change seen
as a result of HTS administration. As mentioned in the
“Materials and methods” section, we performed LPA in
order to assess for any latent class/groupings of response
to HTS administration, evaluating all physiological vari-
ables. This analysis failed to demonstrate any sub-classes
of HTS administrations that were different from the others.
Similarly, we also assessed the correlation between pre-
HTS physiology, using data windows ranging from
10 min up to 2 h pre-HTS, and compared them with the
delta-ICP resulting from HTS administration. As this anal-
ysis was not the focus of the manuscript, it can be found in
Supplementary Appendix D. However, this correlation test-
ing also failed to demonstrate moderate or strong correla-
tions between pre-HTS cerebral physiology and the delta-
ICP response. Predictors of ICP response to the various BTF
guideline-based therapeutics are crucial, as they would al-
low for clinical end-users to stratify patients pre-treatment
into suspected responders vs. non-responders, which may
facilitate alternative treatments or increase in aggressive-
ness of therapies applied. Much further work, using high-
frequency physiological responses, is required in this
Acta Neurochir
regard, and will be the focus of ongoing work from
European [2, 6, 33] and Canadian [8] collaborative research
groups.
Limitations
Despite the interesting results described above, there are some
limitations which deserve highlighting. First, this study is
based on small patient cohort with unique data consisting of
high-frequency digital physiology and available time-linked
HTS administration data. Thus, despite having 69 episodes of
HTS administration, the described results should remain ex-
ploratory at this time. With only 15 patients with 69 HTS
administration events, our data set is small, yet relatively
unique globally with high-frequency physiology linked with
treatment information. Similar methodologies for the explora-
tion of the relationships between TBI therapeutics and contin-
uous physiological responses have been employed by other
centers globally [12, 13, 17, 32, 33, 41, 42]. As these types of
data sets are rare, we are left with exploring such treatment-
related impacts on small patient numbers. This type of analy-
sis, evaluating individual treatment events in a small number
of patients, serve only as a preliminary exploratory probe into
such relationships, and are merely hypothesis generating, re-
quiring much further evaluation using larger multi-center data
sets. As such, the results described within should be
interpreted with caution. Second, we focused on basic statis-
tics and descriptive analysis for the HTS response. Future
work in this area will require time-series techniques, evaluat-
ing the multi-variate relationships pre- and post-treatment.
Third, we evaluated various time windows of physiological
data pre- and post-HTS administration, in order to exclude the
impact of data window length on the relationships seen.
Caution must be taken when evaluating windows for data
averaging that are less than 30 min in duration. Particularly,
evaluating derived correlation indices, such as those for cere-
brovascular reactivity (PRx) and compensatory reserve
(RAP), such caution is required in the interpretation of data
that is averaged using less than 30 min of recordings. Shorter
data windows may not reduce the signal-to-noise ratio suffi-
ciently, particularly in the case of metrics of compensatory
reserve which may take substantially longer to respond to
intervention, compared with other high-frequency physiology
measures such as ICP. Fourth, all patients in this study re-
ceived active treatment according to the BTF guidelines. As
such, the response to HTS seen may not truly reflect the iso-
lated response to HTS but the combination of therapies re-
ceived during the HTS dosing. Furthermore, aggressiveness
of therapy changed throughout these patients stay, based on
ICP/CPP responses and serial cranial imaging. As such, we
cannot confidently say that the physiological responses seen
during HTS administration were solely due to HTS. This fur-
ther highlights the need for large multi-center data sets to
evaluate the impact of all BTF based therapeutic strategies
on cerebrovascular reactivity and compensatory reserve.
Finally, the small number of episodes where ICP was non-
responsive to HTS dosing remain puzzling. The results from
this sub-group require further investigation, as there were only
14 episodes where this occurred.
Future directions
As this is only the second study evaluating the impact of
hypertonic saline dosing on cerebrovascular reactivity, and
compensatory reserve, there exists the need for much further
work. Such work will require larger multi-center datasets,
with treatment data temporally linked. Such work is the focus
of the Canadian High-Resolution TBI (CAHR-TBI) Research
Collaborative. Furthermore, as mentioned above, future inves-
tigation would benefit from time-series analytical methodolo-
gies, using multi-variate vector autoregressive integrative
moving average (VARIMA) models, impulse response func-
tion analysis, and Granger causality testing both pre- and post-
HTS. Such complex work is the focus of ongoing efforts in
our laboratory. In addition, despite the lack of significant re-
sults in this work, LPA is a technique to profile and identify
key features within systems that may help differentiate distinct
responses to an event. To leverage this more effectively, an
increase in sample size may identify more individualized
physiological responses. With larger datasets, we may find
sub-groups of responders to HTS. Finally, the addition of
other continuous multi-modal monitoring would allow us to
comment on the impacts of HTS on cerebral blood flow ve-
locity, cerebral oxygen saturations and extracellular oxygen
diffusion, cerebral blood flow, and cerebral metabolic re-
sponse in the extracellular space. It is only through such com-
plex datasets that we will truly gain an understanding of the
impact of current TBI therapeutics on cerebral physiology,
allowing us to move closer to personalized medicine in
moderate/severe TBI care.
Conclusions
HTS bolus dosing leads to a consistent decrease in ICP and
AMP, with an improvement in CPP. Cerebrovascular reactiv-
ity appears to improve with HTS dosing, but only in those
with grossly impaired reactivity pre-HTS. There is a trend
towards worse cerebrovascular reactivity after HTS adminis-
tration in those patients with intact reactivity pre-HTS. Future
investigation is required to fully demonstrate the underlying
effects.
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